Lantheus Stock Price, News & Analysis (NASDAQ:LNTH)

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Lantheus Holdings Inc (NASDAQ:LNTH) posted its quarterly earnings results on Thursday, July, 25th. The medical equipment provider reported $0.27 EPS for the quarter, meeting the consensus estimate of $0.27. The medical equipment provider had revenue of $85.70 million for the quarter, compared to analysts' expectations of $88.72 million. Lantheus had a net margin of 11.20% and a return on equity of 51.08%. Lantheus's revenue was up .1% on a year-over-year basis. During the same period in the previous year, the company posted $0.25 EPS. View Lantheus' Earnings History.

Lantheus is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Lantheus.

Lantheus updated its FY19 earnings guidance on Thursday, July, 25th. The company provided earnings per share (EPS) guidance of $1.09-1.12 for the period, compared to the Thomson Reuters consensus estimate of $1.12. The company issued revenue guidance of $346-350 million, compared to the consensus revenue estimate of $360.07 million.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lantheus.

Press coverage about LNTH stock has trended somewhat negative recently, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Lantheus earned a news impact score of -1.3 on InfoTrie's scale. They also gave news headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Lantheus.

Lantheus saw a increase in short interest in August. As of August 15th, there was short interest totalling 1,497,300 shares, an increase of 35.8% from the July 15th total of 1,102,200 shares. Based on an average daily volume of 445,200 shares, the short-interest ratio is currently 3.4 days. Currently, 4.1% of the shares of the stock are short sold. View Lantheus' Current Options Chain.

Some companies that are related to Lantheus include Neogen (NEOG), Immunomedics (IMMU), Quidel (QDEL), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Heska (HSKA), Quotient (QTNT), Meridian Bioscience (VIVO), Oxford Immunotec Global (OXFD), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Vermillion (VRML), ImmuCell (ICCC), Celldex Therapeutics (CLDX) and Trinity Biotech (TRIB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include Mobileye (MBBYF), CBL & Associates Properties (CBL), Gerdau (GGB), Energy Transfer LP Unit (ET), Ares Capital (ARCC), Cypress Semiconductor (CY), Endocyte (ECYT), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL) and Exelixis (EXEL).

(LNTH) raised $75 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

Lantheus' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.74%), Vanguard Group Inc. (6.88%), Price T Rowe Associates Inc. MD (5.73%), Renaissance Technologies LLC (4.60%), Invesco Ltd. (3.85%) and LSV Asset Management (3.80%). Company insiders that own Lantheus stock include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, John W Crowley, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Sam R Leno and Timothy G Healey. View Institutional Ownership Trends for Lantheus.

LNTH stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Tamarack Advisers LP, LSV Asset Management, Vaughan Nelson Investment Management L.P., AQR Capital Management LLC, AlphaOne Investment Services LLC, Connor Clark & Lunn Investment Management Ltd. and Cubist Systematic Strategies LLC. Company insiders that have sold Lantheus company stock in the last year include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, Mary Anne Heino, Michael P Duffy and Sam R Leno. View Insider Buying and Selling for Lantheus.

LNTH stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Price T Rowe Associates Inc. MD, Renaissance Technologies LLC, JPMorgan Chase & Co., Prudential Financial Inc., Vanguard Group Inc., Morgan Stanley and Landscape Capital Management L.L.C.. View Insider Buying and Selling for Lantheus.

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LNTH stock can currently be purchased for approximately $26.38.

Lantheus has a market capitalization of $1.02 billion and generates $343.37 million in revenue each year. The medical equipment provider earns $40.51 million in net income (profit) each year or $0.94 on an earnings per share basis. Lantheus employs 488 workers across the globe.View Additional Information About Lantheus.

The official website for Lantheus is http://www.lantheus.com/.

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]